Scientific Advisory Board

Dr. Alan Lumsden

M.D.

Dr. Alan B. Lumsden, M.D., is the Walter W. Fondren III Chair, Medical Director of the Houston Methodist DeBakey Heart & Vascular Center and chair of the Department of Cardiovascular Surgery at Houston Methodist Hospital. He received his Bachelor of Medicine and Surgery at the University of Edinburgh where he graduated at the top of his class. After completing a year-long internship, he moved to Emory University in Atlanta where he completed his surgical residency and vascular training and eventually became the Chief of the Division of Vascular Surgery. In 2002, he joined Michael E. DeBakey Department of Surgery at Baylor College of Medicine as Professor and Chief of the Division of Vascular Surgery and
Endovascular Therapy. He assumed his positions at Houston Methodist Hospital in 2008.

Dr. Lumsden has developed an international reputation as a leader in the field of endovascular surgery. He conducts FDA mandated training for surgeons nationwide and has received significant funding for his research from the National Institutes of Health. He has contributed more than 200 papers to medical literature.

Dr. Norman Wong

M.D.

Dr. Norman C. W. Wong, B.Sc (Hon), M.Sc, M.D., FRCP(C) is a Co-Founder of Resverlogix Corp. (TSX:RVX), and has been its Chief Scientific Officer since 2003. Dr. Wong serves as Professor of Medicine and Biochemistry & Molecular Biology as well as the Director of the Libin Gene/Cell Therapy Unit within the Faculty of Medicine at the University of Calgary. Dr. Wong has been associated with the University of Calgary since 1987 and also has held the posts of Associate Vice-President of Research and International and Assistant Dean (Research) Faculty of Medicine.

Dr. Wong specializes in the areas of: Endocrinology, Internal Medicine, Molecular Biology, and Gene/Cell Therapy. His most recent successes have come from elucidating the potential therapeutic opportunities for cardiovascular disease by examining the epigenetic mechanisms underlying this deadly disease. He has been the author and co-author of more than 275 articles and abstracts and has been invited to sit on more than 40 national or international panels and committees. He has also acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories. Dr. Wong also previously served as a member of the SAB at Hemostemix. Dr. Wong graduated with a Bachelor of Science degree with honors at the University of Calgary in 1975. He subsequently obtained a Master of Science degree in Medical Biochemistry in 1977 and a Medical Degree in 1980, also from the University of Calgary.

Dr. Kumar L. Hari

PhD

Dr. Hari’s expertise spans chromosome biology, functional genomics, and bioinformatics. Dr. Hari has been the Chief Science Officer at cBio Corp. (“cBio”), a private company that provided infectious disease diagnostics and tracking. At cBio, Dr. Hari led the team in engagements with the FDA, various universities and other US government organization. Prior to working at cBio, he held business development and program management roles at Ibis Biosciences, Inc., and Abbott Molecular, Inc., where his work led directly to the spin-off of cBio. Dr. Hari has been a director of program management efforts at the California Institute of Regenerative Medicine and at the Myelin Repair Foundation. Dr. Hari earned his PhD in Cell Biology from UC San Diego and a B.Sc. in Genetics from UC Davis.

Dr. Hari provided due diligence support when evaluating Hemostemix’s science, therapeutic products and clinical trials. He has already provided invaluable guidance and perspective on Hemostemix’s research and development efforts, as well as clinical development programs.